Genital Herpes: A Review

 

Am Fam Physician. 2016 Jun 1;93(11):928-934.

  Patient information: See related handout on genital herpes, written by the author of this article.

Author disclosure: No relevant financial affiliations.

Genital herpes is a common sexually transmitted disease, affecting more than 400 million persons worldwide. It is caused by herpes simplex virus (HSV) and characterized by lifelong infection and periodic reactivation. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving. Symptoms of primary infection may include malaise, fever, or localized adenopathy. Subsequent outbreaks, caused by reactivation of latent virus, are usually milder. Asymptomatic shedding of transmissible virus is common. Although HSV-1 and HSV-2 are indistinguishable visually, they exhibit differences in behavior that may affect management. Patients with HSV-2 have a higher risk of acquiring human immunodeficiency virus (HIV) infection. Polymerase chain reaction assay is the preferred method of confirming HSV infection in patients with active lesions. Treatment of primary and subsequent outbreaks with nucleoside analogues is well tolerated and reduces duration, severity, and frequency of recurrences. In patients with HSV who are HIV-negative, treatment reduces transmission of HSV to uninfected partners. During pregnancy, antiviral prophylaxis with acyclovir is recommended from 36 weeks of gestation until delivery in women with a history of genital herpes. Elective cesarean delivery should be performed in laboring patients with active lesions to reduce the risk of neonatal herpes.

Genital herpes is a common sexually transmitted disease caused by herpes simplex virus (HSV) and characterized by lifelong infection and periodic reactivation. HSV, a DNA virus, is named from its protein coat as HSV-1 or HSV-2. HSV-1 is the chief cause of orolabial herpes. Until recently, genital herpes was more likely to be caused by HSV-2. However, the incidence of primary genital infection with HSV-1 is now as common or more common than HSV-2 in the United States.1

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Type-specific laboratory confirmation of HSV is recommended in patients with clinical disease to guide counseling and management.

C

1, 24, 29

Polymerase chain reaction assay is the preferred test for confirming HSV in clinically apparent lesions.

C

24, 26, 27, 29

Type-specific serologic testing should be offered to partners of patients with HSV infection to determine the risk of HSV acquisition.

C

15, 24, 29

Suppressive therapy reduces symptom severity, duration, and recurrence in patients with genital herpes. In HIV-negative patients, it is also effective in reducing transmission to at-risk partners.

A

24, 32

In persons with HIV and HSV-2 infections, suppressive therapy does not reduce the transmission of HSV-2 to at-risk partners.

B

24, 36


HIV = human immunodeficiency virus; HSV = herpes simplex virus.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Type-specific laboratory confirmation of HSV is recommended in patients with clinical disease to guide counseling and management.

C

1, 24, 29

Polymerase chain reaction assay is the preferred test for confirming HSV in clinically apparent lesions.

C

24, 26, 27, 29

Type-specific serologic testing should be offered to partners of patients with HSV infection to determine the risk of HSV acquisition.

C

15, 24, 29

Suppressive therapy reduces symptom severity, duration, and recurrence in patients with genital herpes. In HIV-negative patients, it is also effective in reducing transmission to at-risk partners.

A

24, 32

In persons with HIV and HSV-2 infections, suppressive therapy does not reduce the transmission of HSV-2 to at-risk partners.

B

24, 36


HIV = human immunodeficiency virus; HSV = herpes simplex virus.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Epidemiology

Worldwide, more than 400 million persons have genital herpes caused by HSV-2.2 In the United States, nearly one in five adults (approximately 50 million persons) has HSV-2 infection, with 1 million new infections occurring each year.35 Overall seroprevalence of HSV-1 is decreasing because of less childhood exposure to orolabial herpes; however, genital acquisition rates have increased simultaneously, with HSV-1 now representing at least one-half of new cases.1,68 This increase has been partly attributed to changing adolescent sexual practices involving more oral-genital contact.8,9

The risk of genital herpes varies by race, sex, and ethnicity. Risk factors, including the number of lifetime sex partners, are listed in Table 1.3,10

 Enlarge     Print

Table 1.

Risk Factors for Genital HSV Infection

Risk factorRisk increase/prevalence

Black, non-Hispanic

Three to four times the prevalence of non-Hispanic whites and Mexican-Americans

Female sex

Twice the prevalence of males

Hormonal contraception use, bacterial vaginosis, and vaginal group B streptococcus colonization

Each factor increases OR of shedding HSV-2:

Hormonal contraception increases OR to 1.5

Bacterial vaginosis increases OR to 2.0

Group B streptococcus increases OR to 2.3

Number of lifetime sex partners

Increase in HSV-2 infection prevalence:

1 partner: 2% to 5%

2 to 4 partners: 7% to 19%

5 to 9 partners: 10% to 22%

≥ 10 partners: 19% to 37%

Oral-genital contact

Increases risk of transmitting HSV-1 from latent or active infection at oral site to genital site of uninfected partner

Presence of other sexually transmitted diseases

Increases OR of shedding to 3.1


HSV = herpes simplex virus; OR = odds ratio.

Information from references 3 and 10.

Table 1.

Risk Factors for Genital HSV Infection

Risk factorRisk increase/prevalence

Black, non-Hispanic

Three to four times the prevalence of non-Hispanic whites and Mexican-Americans

Female sex

Twice the prevalence of males

Hormonal contraception use, bacterial vaginosis, and vaginal group B streptococcus colonization

Each factor increases OR of shedding HSV-2:

Hormonal contraception increases OR to 1.5

Bacterial vaginosis increases OR to 2.0

Group B streptococcus increases OR to 2.3

Number of lifetime sex partners

Increase in HSV-2 infection prevalence:

1 partner: 2% to 5%

2 to 4 partners: 7% to 19%

5 to 9 partners: 10% to 22%

≥ 10 partners: 19% to 37%

Oral-genital contact

Increases risk of transmitting HSV-1 from latent or active infection at oral site to genital site of uninfected partner

Presence of other sexually transmitted diseases

Increases OR of shedding to 3.1


HSV = herpes simplex virus; OR = odds ratio.

Information from references 3 and 10.

Pathophysiology

Primary HSV infection results from a previously unexposed person having close contact with someone who is actively shedding the virus from skin or secretions. There may be a prodrome of hours to days consisting of pain, tingling, itching, or burning at the site of exposure. Epithelial damage at the portal of entry leads to eruption of vesicles that open, ulcerate, and reepithelialize during an outbreak that lasts about two weeks. During initial infection, viral DNA travels by axon to the spinal cord sensory ganglion where it persists for life.8 Reactivation of HSV causes migration back through the axon, its branches, or contralateral axons to the skin and mucosa.11

Clinical Manifestations

A visible outbreak consists of single or clustered vesicles on the genitalia (Figures 1 and 212), perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving. Primary infections may cause malaise, fever, or localized adenopathy. Subsequent outbreaks are usually milder and are caused by reactivation of latent virus.1,3 The classic presentation of HSV, whether primary infection or secondary outbreak, is absent most of the time, with many patients reporting minimal or no symptoms.8 Studies consistently report 65% to 90% of patients with genital HSV infection are unaware of its presence.1,3,13

 Enlarge     Print

Figure 1.

Recurrent herpes simplex virus vesicles on the penis.

Reprinted with permission from Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1529.


Figure 1.

Recurrent herpes simplex virus vesicles on the penis.

Reprinted with permission from Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1529.

 Enlarge     Print

Figure 2.

Recurrent herpes simplex virus erosions on the labia minora.

Reprinted with permission from Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1529.


Figure 2.

Recurrent herpes simplex virus erosions on the labia minora.

Reprinted with permission from Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1529.

Clinically apparent secondary outbreaks may have a prodrome anywhere along the involved axon, are milder, and usually heal within six to 12 days. Primary and secondary genital HSV-1 infections tend to be milder than HSV-2 infections. Patients with HSV-1 infection average zero to one recurrence per year, whereas HSV-2 recurs four to five times annually, with both types decreasing in recurrence over time. The wide variability in clinical expression may have greater significance to the individual's symptomatic course than the viral type.8

Asymptomatic viral shedding is common, occurring on 10% to 20% of all days and more often during the first year of infection, but continuing over the extended years studied.1416 The frequency of subclinical infection and asymptomatic shedding facilitates HSV transmission. The first recognizable outbreak may not occur until well after the primary infection.1,17

Complications

Persons with HSV-2 infection have a threefold increase in the risk of acquiring human immunodeficiency virus (HIV) infection.18 This may be related to open ulcers, or lymphocytes at the site of eruptions, facilitating HIV invasion during sexual contact.19

Concurrent infection with HSV-2 and HIV increases the severity of HSV episodes and the likelihood of atypical presentations.20 The relationship between genital HSV-1 and HIV infections has not been well studied.21

The presence of either HSV-1 or HSV-2 antibody may provide a small degree of protection against developing an infection with the other HSV type at the same or a new site; however, patients should still be counseled on safe sex practices to prevent genital infections.7,8

Complications of genital herpes are listed in Table 2.8 However, the predominant morbidity may be the psychological burden attributable to lifelong dilemmas of conduct, and disclosure to sex partners.8,22,23

 Enlarge     Print

Table 2.

Complications of Genital Herpes

Acute urinary retention (particularly in women)

Aseptic meningitis (including a recurrent form)

Disseminated herpes

Encephalitis

Hepatitis

Neonatal infection

Pelvic inflammatory disease

Pneumonitis


Information from reference 8.

Table 2.

Complications of Genital Herpes

Acute urinary retention (particularly in women)

Aseptic meningitis (including a recurrent form)

Disseminated herpes

Encephalitis

Hepatitis

Neonatal infection

Pelvic inflammatory disease

Pneumonitis


Information from reference 8.

Diagnosis

Although herpes is the most common ulcerative genital disease in the United States, the coexistence of multiple etiologies must be considered. Table 3 lists the differential diagnosis.24,25 Because HSV-1 and HSV-2 infections are indistinguishable visually, suspected infection should be confirmed by type-specific testing to guide management.1,24 In the presence of active lesions, polymerase chain reaction assay is the preferred test, with sensitivity and specificity greater than 95%.24,26,27

 Enlarge     Print

Table 3.

Differential Diagnosis of Genital Ulcers

Infectious

Chancroid

Fungal infection

Genital herpes simplex

Granuloma inguinale

Lymphogranuloma venereum

Secondary bacterial infection

Syphilis

Noninfectious

Aphthous ulcers

Behçet syndrome

Fixed drug eruption

Neoplasms

Psoriasis

Sexual trauma


Information from references 24 and 25.

Table 3.

Differential Diagnosis of Genital Ulcers

Infectious

Chancroid

Fungal infection

Genital herpes simplex

Granuloma inguinale

Lymphogranuloma venereum

Secondary bacterial infection

Syphilis

Noninfectious

Aphthous ulcers

Behçet syndrome

Fixed drug eruption

Neoplasms

Psoriasis

Sexual trauma


Information from references 24 and 25.

Serologic testing may be useful if there is a history of suggestive symptoms but no lesions are present or polymerase chain reaction assay results are negative, or when the patient's partner is infected.24  Western blot is the diagnostic standard, although glycoprotein G tests are comparable (Table 4).28 Older immunoglobulin G and M antibody tests are not reliable and should not be used.28

 Enlarge     Print

Table 4.

Recommended HSV Type-Specific Antibody Tests

TestSensitivity (%)Specificity (%)Availability

HerpeSelect 1 and 2 ELISA

96 to 100

97 to 100

Commercial

HerpeSelect 1 and 2 Immunoblot

97 to 100

98

Commercial

POCkit-HSV-2

93 to 100

94 to 97

Point of care


ELISA = enzyme-linked immunosorbent assay; HSV = herpes simplex virus.

Adapted with permission from Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(suppl 2):S174.

Table 4.

Recommended HSV Type-Specific Antibody Tests

TestSensitivity (%)Specificity (%)Availability

HerpeSelect 1 and 2 ELISA

96 to 100

97 to 100

Commercial

HerpeSelect 1 and 2 Immunoblot

97 to 100

98

Commercial

POCkit-HSV-2

93 to 100

94 to 97

Point of care


ELISA = enzyme-linked immunosorbent assay; HSV = herpes simplex virus.

Adapted with permission from Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(suppl 2):S174.

There is a window of two weeks to six months after HSV exposure to formation of detectable antibody, so repeat serologic testing may be needed to confirm recent acquisition. When the likelihood of infection is low, false-positive test results are more common. It is unclear how to counsel patients with a positive serologic test result but no history of genital herpes symptoms.29 Therefore, the U.S. Preventive Services Task Force and the Centers for Disease Control and Prevention (CDC) recommend against serologic screening for genital herpes.24,30 Type-specific serologic testing should be offered to partners of patients with HSV infection to determine the risk of acquisition15,24,29  (Table 5 31).

 Enlarge     Print

Table 5.

Scenarios to Consider Herpes Simplex Virus Type-Specific Serologic Testing

Patients with recurrent genital symptoms or atypical symptoms and negative herpes simplex virus polymerase chain reaction assay or culture

Patients with a clinical diagnosis of genital herpes but no laboratory confirmation

Patients who report having a partner with genital herpes

Patients presenting for a sexually transmitted disease evaluation (especially those with multiple sex partners)

Persons with human immunodeficiency virus infection

Men who have sex with men who are at increased risk of human immunodeficiency virus acquisition


Information from reference 31.

Table 5.

Scenarios to Consider Herpes Simplex Virus Type-Specific Serologic Testing

Patients with recurrent genital symptoms or atypical symptoms and negative herpes simplex virus polymerase chain reaction assay or culture

Patients with a clinical diagnosis of genital herpes but no laboratory confirmation

Patients who report having a partner with genital herpes

Patients presenting for a sexually transmitted disease evaluation (especially those with multiple sex partners)

Persons with human immunodeficiency virus infection

Men who have sex with men who are at increased risk of human immunodeficiency virus acquisition


Information from reference 31.

Interpretation of serology results is critical to accurately counsel patients. Serology confirms infection and the viral type. Because HSV-2 is almost always genitally acquired, the presence of HSV-2 antibody implies anogenital disease, even if there is no history of symptoms.24 However, the site of HSV-1 infection cannot be identified by positive HSV-1 serology results alone.5,24 HSV-1 antibody is present in 54% of the U.S. population, primarily acquired orolabially in childhood,5 and it is often asymptomatic whether orolabial or genital. Considering the increased incidence of new genital HSV-1 infections and changing sexual practices, clinicians should counsel patients who test positive for HSV-1 antibody that they may be able to transmit HSV to uninfected partners through oral or genital sex, and that they remain at risk of acquiring HSV-2 infection.8,24

Treatment and Prevention

Episodic and suppressive treatment of herpes is aimed at reducing the severity, duration, and recurrence of symptoms, and at preventing transmission to uninfected partners.24,32 Suppressive treatment may be intermittent or continuous. Three nucleoside analogues, which work by inhibiting viral DNA, are approved and well tolerated: acyclovir, famciclovir (Famvir), and valacyclovir (Valtrex). Regimens are identical for HSV-1 and HSV-2.

Nucleoside analogues are equally effective in treating first and subsequent episodes of HSV infection, in reducing the frequency and severity of recurrence, and in decreasing viral shedding.24,3335 However, shedding is not completely eliminated with any treatment regimen, nor does treatment eliminate latent virus or affect transmission risk or symptoms once the medication is discontinued.24 Oral regimens32  recommended in the 2015 CDC guidelines are provided in Tables 6, 7, and 8.24

 Enlarge     Print

Table 6.

Recommended Treatment Options for First Clinical Episode of Genital Herpes

Drug and doseFrequencyDuration*Cost

Acyclovir, 400 mg

Three times per day

7 to 10 days

$10

Acyclovir, 200 mg

Five times per day

7 to 10 days

$10

Famciclovir (Famvir), 250 mg

Three times per day

7 to 10 days

$70 ($350)

Valacyclovir (Valtrex), 1 g

Twice per day

7 to 10 days

$100 ($400)


*—Treatment can be extended if healing is incomplete after 10 days.

†—Estimated retail price for 10 days of treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

Table 6.

Recommended Treatment Options for First Clinical Episode of Genital Herpes

Drug and doseFrequencyDuration*Cost

Acyclovir, 400 mg

Three times per day

7 to 10 days

$10

Acyclovir, 200 mg

Five times per day

7 to 10 days

$10

Famciclovir (Famvir), 250 mg

Three times per day

7 to 10 days

$70 ($350)

Valacyclovir (Valtrex), 1 g

Twice per day

7 to 10 days

$100 ($400)


*—Treatment can be extended if healing is incomplete after 10 days.

†—Estimated retail price for 10 days of treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

 Enlarge     Print

Table 7.

Episodic Treatment Options for Recurrent Genital Herpes*

Drug and doseFrequencyDurationCost

Acyclovir, 400 mg

Three times per day

5 days

$10

Acyclovir, 800 mg

Twice per day

5 days

$10

Acyclovir, 800 mg

Three times per day

2 days

$10

Famciclovir (Famvir), 125 mg

Twice per day

5 days

$30 ($115)

Famciclovir, 1 g

Twice per day

1 day

$25 ($100)

Famciclovir, 500 mg and 250 mg

Single dose of 500 mg on day 1, followed by 250 mg twice per day on days 2 and 3

3 days

$20 ($75)

Valacyclovir (Valtrex), 500 mg

Twice per day

3 days

$20 ($75)

Valacyclovir, 1 g

Once per day

5 days

$30 ($100)


*—Requires initiation of medication with prodrome preceding outbreak or within one day of lesion onset. The patient should be provided a supply of medication or a prescription for the medication to initiate treatment immediately with symptoms.

†—Estimated retail price of treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

Table 7.

Episodic Treatment Options for Recurrent Genital Herpes*

Drug and doseFrequencyDurationCost

Acyclovir, 400 mg

Three times per day

5 days

$10

Acyclovir, 800 mg

Twice per day

5 days

$10

Acyclovir, 800 mg

Three times per day

2 days

$10

Famciclovir (Famvir), 125 mg

Twice per day

5 days

$30 ($115)

Famciclovir, 1 g

Twice per day

1 day

$25 ($100)

Famciclovir, 500 mg and 250 mg

Single dose of 500 mg on day 1, followed by 250 mg twice per day on days 2 and 3

3 days

$20 ($75)

Valacyclovir (Valtrex), 500 mg

Twice per day

3 days

$20 ($75)

Valacyclovir, 1 g

Once per day

5 days

$30 ($100)


*—Requires initiation of medication with prodrome preceding outbreak or within one day of lesion onset. The patient should be provided a supply of medication or a prescription for the medication to initiate treatment immediately with symptoms.

†—Estimated retail price of treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

 Enlarge     Print

Table 8.

Suppressive Treatment Options for Recurrent Genital Herpes

Drug and doseFrequencyCost*

Acyclovir, 400 mg

Twice per day

$20

Famciclovir (Famvir), 250 mg

Twice per day

$150 ($725)

Valacyclovir (Valtrex), 500 mg†

Once per day

$40 ($325)

Valacyclovir, 1 g

Once per day

$100 ($575)


*—Estimated retail price of one month's treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

†—Valacyclovir, 500 mg once per day, may be less effective than other valacyclovir or acyclovir regimens in persons with very frequent episodes (i.e., more than 10 episodes per year).

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

Table 8.

Suppressive Treatment Options for Recurrent Genital Herpes

Drug and doseFrequencyCost*

Acyclovir, 400 mg

Twice per day

$20

Famciclovir (Famvir), 250 mg

Twice per day

$150 ($725)

Valacyclovir (Valtrex), 500 mg†

Once per day

$40 ($325)

Valacyclovir, 1 g

Once per day

$100 ($575)


*—Estimated retail price of one month's treatment based on information obtained at http://www.goodrx.com (accessed February 10, 2016). Generic price listed first; brand price listed in parentheses.

†—Valacyclovir, 500 mg once per day, may be less effective than other valacyclovir or acyclovir regimens in persons with very frequent episodes (i.e., more than 10 episodes per year).

Adapted from Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

In patients who have both HSV-2 and HIV infections, anti-HSV suppressive therapy does not reduce the risk of HSV transmission to uninfected partners.36 Also, suppressive therapy in patients with HSV-2 infection does not reduce the risk of acquiring HIV infection.37

Treatment should be based on the patient's disease profile, sexual practices, and psychosocial needs. Persons with infrequent or mild recurrences may opt for episodic treatment. Patient-initiated episodic treatment in those with known genital herpes is safe and effective, and avoids delay in initiating treatment.38 Chronic suppression is valuable for patients with frequent recurrences and for protecting at-risk partners. Drug resistance with long-term nucleoside analogue use is rare in immunocompetent persons.39 Topical acyclovir has minimal benefit for local symptom reduction, and does not improve episode duration, recurrence, or transmission rates.24,40

There are no approved vaccines for the treatment or prevention of genital herpes. Key points for counseling patients with genital herpes are listed in Table 9.24

 Enlarge     Print

Table 9.

Key Points for Counseling Patients with Genital Herpes

Patients should be educated on the atypical and subtle signs of herpes outbreaks because it improves recognition. They should be advised to abstain from sex with uninfected partners when active lesions or prodromal symptoms are present.

Patients should be counseled to inform current sex partners about genital herpes and to inform future partners before initiating a sexual relationship.

Patients should be informed of the high incidence of asymptomatic viral shedding and the likelihood of transmitting HSV in the absence of an active outbreak.

Infection with HSV increases the risk of acquiring HIV infection.

In patients with HSV-2 and HIV infections, episodic or suppressive treatment is not effective in preventing HSV transmission to at-risk partners.

In HIV-negative persons with HSV infection, suppressive therapy and sexual abstinence during apparent outbreak and prodrome reduce the risk of HSV transmission.

Consistent use of male latex condoms reduces the risk of HSV transmission.

Asymptomatic partners of patients with HSV infection should be counseled on HSV and offered type-specific serologic testing.


HIV = human immunodeficiency virus; HSV = herpes simplex virus.

Information from reference 24.

Table 9.

Key Points for Counseling Patients with Genital Herpes

Patients should be educated on the atypical and subtle signs of herpes outbreaks because it improves recognition. They should be advised to abstain from sex with uninfected partners when active lesions or prodromal symptoms are present.

Patients should be counseled to inform current sex partners about genital herpes and to inform future partners before initiating a sexual relationship.

Patients should be informed of the high incidence of asymptomatic viral shedding and the likelihood of transmitting HSV in the absence of an active outbreak.

Infection with HSV increases the risk of acquiring HIV infection.

In patients with HSV-2 and HIV infections, episodic or suppressive treatment is not effective in preventing HSV transmission to at-risk partners.

In HIV-negative persons with HSV infection, suppressive therapy and sexual abstinence during apparent outbreak and prodrome reduce the risk of HSV transmission.

Consistent use of male latex condoms reduces the risk of HSV transmission.

Asymptomatic partners of patients with HSV infection should be counseled on HSV and offered type-specific serologic testing.


HIV = human immunodeficiency virus; HSV = herpes simplex virus.

Information from reference 24.

Considerations in Pregnancy

One in five pregnant women is seropositive for HSV-2, and more than 60% of pregnant women are positive for HSV-1.41 Yet, neonatal herpes is uncommon, occurring once in 3,200 live births. However, maternal primary infection with HSV-1 or HSV-2 at the time of delivery carries a 60% risk of neonatal herpes.

Antiviral prophylaxis with acyclovir is recommended from 36 weeks' gestation until delivery in women with a history of genital herpes to minimize active recurrence at the time of delivery.42 All three nucleoside analogues are U.S. Food and Drug Administration category B for breastfeeding and pregnancy. Elective cesarean delivery should be performed in laboring patients with active lesions to decrease the risk of HSV transmission.42

Data Sources: PubMed was searched using the key terms genital herpes, diagnosis, testing, prognosis, treatment, clinical features, pregnancy, neonatal herpes, and vaccines. Also searched were the Cochrane database, Essential Evidence Plus, Clinical Key, Clinical Evidence, the Centers for Disease Control and Prevention website and selected issues of Morbidity and Mortality Weekly Report for 2015 STD treatment guidelines and epidemiologic data. Search dates: June 2015 through March 2016.

The Author

MARY JO GROVES, MD, is a clinical associate professor of family medicine at Wright State University Boonshoft School of Medicine, Dayton, Ohio.

Author disclosure: No relevant financial affiliations.

Address correspondence to Mary Jo Groves, MD, Wright State University Boonshoft School of Medicine, 3640 Colonel Glenn Hwy., Dayton, OH 45435. Reprints are not available from the author.

REFERENCES

show all references

1. Bernstein DI, Bellamy AR, Hook EW III, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56(3):344–351....

2. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012 [published correction appears in PLoS One. 2015;10(5):e0128615]. PLoS One. 2015;10(1):e114989.

3. Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years—United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456–459.

4. Satterwhite CL, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–193.

5. Bradley H, et al. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014;209(3):325–333.

6. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–973.

7. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137.

8. Corey L, Wald A. Genital herpes. In: Holmes KK, Sparling PF, Stamm WE, et al. Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw Hill Medical; 2008:399–438.

9. Halpern-Felsher BL, Cornell JL, Kropp RY, Tschann JM. Oral versus vaginal sex among adolescents: perceptions, attitudes, and behavior. Pediatrics. 2005;115(4):845–851.

10. Cherpes TL, et al. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis. 2005;40(10):1422–1428.

11. Tata S, Johnston C, Huang ML, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis. 2010;201(4):499–504.

12. Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1527–1534.

13. Schillinger JA, McKinney CM, Garg R, et al. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis. 2008;35(6):599–606.

14. Tronstein E, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441–1449.

15. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis. 2003;30(2):174–177.

16. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011;203(2):180–187.

17. Diamond C, et al. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis. 1999;26(4):221–225.

18. Freeman EE, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73–83.

19. Corey L. Synergistic copathogens—HIV-1 and HSV-2 [published correction appears in N Engl J Med. 2007; 356(14):1487]. N Engl J Med. 2007;356(8):854–856.

20. Leeyaphan C, et al. Clinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int J Infect Dis. 2015;33:165–170.

21. Tan DH, Kaul R, Walsmley S. Left out but not forgotten: should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV? Can J Infect Dis Med Microbiol. 2009;20(1):e1–e7.

22. Dunphy K. Herpes genitalis and the philosopher's stance. J Med Ethics. 2014;40(12):793–797.

23. Gilbert LK, Omisore F. Common questions about herpes: analysis of chat-room transcripts. Herpes. 2009;15(3):57–61.

24. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections. http://www.cdc.gov/std/tg2015/herpes.htm. Accessed March 1, 2016.

25. Johnston C, Morrow RA, Moreland A, Wald A. Genital herpes. In: Morse SA, Ballard RC, Holmes KK, Moreland AA, eds. Atlas of Sexually Transmitted Diseases and AIDS. 4th ed. London, UK: Saunders Elsevier; 2010:169–185.

26. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect. 2002;78(1):21–25.

27. Wald A, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188(9):1345–1351.

28. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(suppl 2):S173–S182.

29. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transm Infect. 2002;78(3):160–165.

30. U.S. Preventive Services Task Force. Final update summary: Genital herpes: Screening. March 2005. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/genital-herpes-screening. Accessed October 7, 2015.

31. Centers for Disease Control and Prevention. Genital herpes—CDC fact sheet (detailed). http://www.cdc.gov/std/herpes/stdfact-herpes-detailed.htm. Accessed March 1, 2016.

32. Hollier LM, Eppes C. Genital herpes: Oral antiviral treatments. BMJ Clin Evid. 2015;2015:1603.

33. Corey L, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes. 2007;14(suppl 1):5A–11A.

34. Lebrun-Vignes B, et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238–246.

35. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168(11):1137–1144.

36. Mujugira A, Magaret AS, Celum C, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis. 2013;208(9):1366–1374.

37. Celum C, Wald A, Hughes J, et al.; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109–2119.

38. Abudalu M, Tyring S, Koltun W, Bodsworth N, Hamed K. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis. 2008;47(5):651–658.

39. Reyes M, Shaik NS, Graber JM, et al.; Task Force on Herpes Simplex Virus Resistance. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med. 2003;163(1):76–80.

40. Kinghorn GR, Turner EB, Barton IG, Potter CW, Burke CA, Fiddian AP. Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes. Antiviral Res. 1983;3(5–6):291–301.

41. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the united states. Am J Obstet Gynecol. 2007;196(1):43.e1–e6.

42. Stephenson-Famy A, Gardella C. Herpes simplex virus infection during pregnancy. Obstet Gynecol Clin North Am. 2014;41(4):601–614.

 

 

Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP

More in Pubmed

MOST RECENT ISSUE


Sep 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article